This proposed rule is no longer the most current information.
It will continue to be available for reference, but the
final rule has been published. View
the final rule.
|
A. Compliance Testing
We have identified three levels of testing that must be addressed
in connection with the adoption and implementation of the standards
we are proposing and their required code sets:
Level 1--Developmental Testing--This is the testing done by the
standards setting organization during the development process. The
conditions for, and results of, this testing are made public by
the relevant standards bodies, and are available at the following
Internet web site:
http://www.disa.org
The information on the web site is provided at the discretion of
the standards setting organization and could, among other things,
refer to pilot, limited, or large-scale production if appropriate.
Information regarding code set testing will also be posted to a
website. This website will be advertised on the HCFA home page.
Level 2--Validation Testing--This is testing of sample transactions
to see whether they are being written correctly. We expect that
private industry will provide commercial testing at this level.
This level of testing would give the participants a sense of whether
they are meeting technical specifications of structure and syntax
for a transaction, but it may not necessarily test for valid data.
This type of testing would inform individuals that the transaction
probably meets the specifications. These edits would be less rigorous
than those that might be applied by a health plan before payment
(in the case of a claim) or by a health care provider prior to posting
(in the case of a health care claim payment/advice). The test conditions
and results from this level are generally shared only between the
parties involved.
Level 3--Production Testing--This tests a transaction from a sender
through the receivers system. The test information is exposed
to all of the edits, lookups, and checks that the transaction would
undergo in a production situation. The test conditions and results
from this level are generally shared only between the parties involved.
Pilot production--Billions of dollars change hands each year as
a result of health care claims processing alone. For that reason,
we believe the industry should sponsor pilot production projects
to test transaction standards that are not currently in full production
prior to the effective date for adoption. Pilot production tests
are not necessary for the NCPDP retail pharmacy claim since it is
already in widespread use. On the other hand, some of the ASC X12N
implementations have not yet been placed in general production.
We believe that pilot production results should be posted on a website
and show information of general interest to potential users. The
information given is at the discretion of the entities conducting
the pilot and might contain information regarding the number of
claims processed, the identity of the entities participating in
the pilot, and the name, telephone number or e-mail address of an
individual willing to answer questions from the public.
It would be useful to all participants if pilot production projects
and the results were posted to a web site for all transactions.
For the claim and equivalent encounter transactions, we believe
that posting pilot production projects and results to a web site
must be mandatory.
B. Enforcement
Failure to comply with standards may well result in monetary penalties.
The Secretary is required by statute to impose penalties of not
more than $100 per violation on any person who fails to comply with
a standard, except that the total amount imposed on any one person
in each calendar year may not exceed $25,000 for violations of one
requirement.
We are not proposing any enforcement procedures at this time, but
we will do so in a future Federal Regulations document, once
the industry has some experience with using the standards.
We are at this time, however, soliciting input on appropriate mechanisms
to permit independent assessment of compliance. We are particularly
interested in input from those engaging in health care EDI as well
as from independent certification and auditing organizations addressing
issues of documentary evidence of steps taken for compliance; need
for/desirability of independent verification, validation, and testing
of systems changes; and certifications required for off-the-shelf
products used to meet the requirements of this regulation.
|